Acquisition of one (1) Bio-Rad CFX Opus 96 Real-Time PCR System for the Laboratory of Receptor Biology and Gene Expression Branch (LRBGE), Center for Cancer Research (CCR), National Cancer Institute (NCI)

General Information Document Type:

Presolicitation Synopsis Number:

75N98026Q00517 Posted Date:

June 4, 2026 Original Response Date:

June 15, 2026 Current Response Date:

June 15, 2026 Set Aside:

N/A NAICS Code: 325414 Contracting Office Address National Institutes of Health (NIH), Office of the Director (OD) Office of Logistics and Operations (OLAO) Office of Acquisition and Logistics Management (OALM) Hospital and Laboratory Support Division 6701 Rockledge Drive Bethesda, MD 20817 Description INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to:

Bio-Rad 2000 Alfred Nobel Drive Hercules, CA 94547 NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 325414 with a Size Standard $1250.

REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2026-01, March 13, 2026. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($350,000).

STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

GENERAL INFORMATION Title: Acquisition of one (1) Bio-Rad CFX Opus 96 Real-Time PCR System for the Laboratory of Receptor Biology and Gene Expression Branch (LRBGE), Center for Cancer Research (CCR), National Cancer Institute (NCI)

Background Information: The U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Receptor Biology and Gene Expression Branch (LRBGE) requires one (1) new, commercially available Bio-Rad CFX Opus 96 Real-Time PCR System to replace two existing Bio-Rad CFX96 real-time PCR units that are approximately 10 years old, non-functional, and no longer supported by the manufacturer for repair or service.

The existing qPCR systems have served as core workhorse instruments for several laboratories in LRBGE. Their loss has reduced branch capacity for routine gene expression analysis, experimental quality control assays, and genomics workflows. The replacement instrument is required to restore reliable real-time PCR capability for multiple users and ongoing research programs.

The requested Bio-Rad CFX Opus 96 Real-Time PCR System provides a 96-well, 5-color plus FRET, network-connected real-time PCR detection platform and includes the CFX Opus 96 base unit, cables, and CFX Maestro Software 2.3 for Windows. The system will support plate setup, data collection, statistical analysis, and graphing of results. The replacement platform also offers improved block uniformity and multiplexing compared with the outdated instruments currently being replaced.

Continued use of the Bio-Rad platform is important to maintain compatibility with existing software, established protocols, instrument parameters, and currently held consumables. Acquiring another manufacturer’s system would require revalidation, restandardization, and workflow adjustments that would increase cost, staff burden, and disruption to ongoing research. CLOSING STATEMENT This synopsis is not a request for competitive proposals.

However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, the period of performance, the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size.

All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.

All responses must be received by June 15, 2026 at 9:00 AM Eastern time and must reference solicitation number 75N98026Q00517. Responses may be submitted electronically to Mr. James Law, Contracting Officer at James.Law@nih.gov. Fax responses will not be accepted. "All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.”